SURGICAL REMOVAL OF THE FIBROSIS AND GRAFTING WITH SAPHENOUS VEIN IN TREATING PEYRONIE DISEASE: TWO CASE REPORTS

Nguyen Huu Thao1, Nguyen Quang1, Trinh Hoang Giang1, Luu Quang Long1, Nguyen Tien Dung2, Tran Trung Thanh3, Nguyen Duy Khanh1, Bui Van Quang1, Cao Dac Tuan1
1 Viet Duc University Hospital
2 University of Medicine and Pharmacy - Vietnam National University, Hanoi
3 Hanoi Medical University

Main Article Content

Abstract

Treatment of La Peyronie by plaque incision and by saphenous vein graft is a surgical
method to lengthen the tunica albuginea. This method is currently one of the best methods to
treat La Peyronie. Open surgery to take the saphenous vein graft is still the popular method.
However, by advances in endoscopic surgery, endoscopic saphenous vein graft is applied.
Report of 2 clinical cases: A 68-year-old male patient was diagnosed with La Peyronie.
He had difficulty in sexual intercourse for 3 years. The size of the cavernous sclerosis mass
in the middle of the dorsal penis is 3x2 cm. The surgery takes 150 minutes. The patient
was hospitalized for 7 days. The urinary catheter is kept for 1 day. The femoral drainage
is withdrawn after 6 days. During the hospital stay, there were no haemorrhage and no
infection complications.
A 54-year-old man has a fibrous mass in the middle of the ventral surface of the penis.
The size of the fibrous mass is 2 x 1.5 cm. The surgery takes 120 minutes. The patient
was hospitalized for 7 days. The urinary catheter is kept for 1 day. The femoral drainage
is withdrawn after 6 days. During the hospital stay, there were no haemorrhage and no
infection complications. The patient had edema of the right thigh. After treated with antiinflammatory therapy, the patient was stabilized.
Conclusion: The surgical reconstruction using the saphenous vein graft to treat La Peyronie
is a safe surgical method with the high treatment efficiency. Endoscopic saphenous vein
graft is an effective method to take the saphenous vein.

Article Details

References

[1] Hauck EW, Weidner W, François de la
Peyronie and the disease named after him,
The Lancet, 2001; 357 (9273): 2049-2051.
[2] Nguyễn Quang, Bệnh học nam khoa cơ bản,
Nhà xuất bản Y học, 2012; p156-158.
[3] Gonzalez-Cadavid NF, Rajfer J, Mechanisms
of disease: new insights into the cellular and
molecular pathology of Peyronie’s disease,
Nature Clinical Practice Urology, 2005; 2
(6): 291-297.
[4] Ralph D, Gonzalez‐Cadavid N, Mirone V et
al., The management of Peyronie’s disease:
Evidence‐based 2010 guidelines, The journal
of sexual medicine, 2010; 7 (7): 2359-2374.
[5] Gelbard M, Lipshultz LI, Tursi J et al., Phase
2b study of the clinical efficacy and safety
of collagenase Clostridium histolyticum in
patients with Peyronie disease, J Urol, 2012;
187 (6): 2268-2274.
[6] Kadioglu A, Akman T, Sanli O et al.,
Surgical treatment of Peyronie’s disease: a
critical analysis, European urology, 2006; 50
(2): 235-248.
[7] Kumar R, Nehra A, Surgical and minimally
invasive treatments for Peyronie’s disease,
Current opinion in urology, 2009; 19 (6):
589-594.
[8] Jas Kalsi, The results of plaque incision and
venous grafting (Lue procedure) to correct
the penile deformity of Peyronie’s disease,
BJU International, 2005; 95 (7): 1029-1033.
[9] Kadioglu A, Sanli O, Akman T et al., Graft
materials in Peyronie’s disease surgery: a
comprehensive review. The journal of sexual
medicine, 2007; 4 (3): 581-595.